Endomedix is a pre-clinical MedTech venture located in Montclair, New Jersey. The Company’s PLEXimine™ novel chemistry platform can be tuned to produce 5 separate biosurgery product groups, each with very different characteristics. This versatile technology can be used to produce biosurgical devices that solve problems that can’t be addressed by the legacy devices. Its PLEXimine™ technology uses starting materials with a history of use in FDA-regulated products and imparts to them unique features and characteristics. Its lead product, PlexiClot™ Absorbable Hemostat, is fast acting and eliminates through technology the risk of paralysis and reoperation due to device swelling, a common problem in all current absorbable hemostats. The technology and products are protected by a robust patent estate, with 7 issued patents and 2 published applications to protect its inventions.